Welcome to the AD/PD™ 2024 Interactive Program
The conference will officially run on Western European Standard Time (Lisbon, UTC+0)
To convert the conference times to your local time Click Here
Session Description:
Explore the latest scientific insights and clinical advances in the diagnosis and treatment of alpha-synuclein pathologies at AC Immune’s AD/PD industry symposium. Led by Dr. Andrea Pfeifer, this session brings together leaders in the field to offer a focused examination of the latest advances in the development of a-syn-targeting diagnostics and therapeutics.
The symposium will open with Dr. Werner Poewe presenting recent progress in the diagnosis of synucleinopathies. After that, Dr. Francesca Capotosti will delve into the development of PET tracers for alpha-synucleinopathies.
Switching to the latest advances in treatments for alpha-synuclein pathologies, Dr. Fabrizio Stocchi will provide an overview of new therapeutic approaches in Parkinson's disease, followed by Dr. Elpida Tsika who will focus on the development of Morphomer a-syn small molecule drugs, and Dr. Nuno Mendonça who will present an update from AC Immune’s active immunotherapy targeting alpha-synuclein, ACI-7104.056, which is being evaluated in the Phase 2 clinical trial VacSYn.
The session concludes with an interactive Q&A, providing attendees with the opportunity to engage directly with the speakers. Join us for a scientifically grounded exploration into the evolving landscape of treatments and diagnosis for alpha-synuclein pathologies.